Study of YOLT-203 for Primary Hyperoxaluria Type 1
Part of Genetic & congenital, Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests a new treatment for primary hyperoxaluria type 1, a rare condition that causes too much oxalate in the body, which can lead to kidney stones and kidney damage. The treatment is given as an injection, and the study will see if it is safe and how the body responds.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age at least 6 years
- A confirmed diagnosis of primary hyperoxaluria type 1 (PH1) via genetic testing
- Having a high level of oxalate in the urine, based on an average of two 24-hour urine collections
- If taking vitamin B6, must be on a stable dose for at least 90 days before starting the study
- Must be willing to follow study rules and give written permission (or have a guardian do so for minors)
- Must not have certain health problems or test results that could affect safety, such as severe liver or kidney issues, HIV, hepatitis, or a history of organ transplants, among others
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called YOLT-203 for people with primary hyperoxaluria type 1 (PH1), a rare genetic condition where the body produces too much oxalate, which can damage the kidneys. The trial aims to see if this drug can help reduce oxalate levels and prevent kidney damage.
This Phase 2 study tests a medicine called DCR-PHXC to lower body oxalate levels in people with PH1 who have advanced kidney failure. By lowering oxalate, the treatment may reduce harm from oxalate buildup and help researchers understand safety and effectiveness.
This study tests whether stiripentol can lower oxalate levels in people with primary hyperoxaluria, a rare condition that causes kidney stones and can lead to kidney damage. It may help reduce the risk of kidney failure.
This trial tests an experimental drug called YOLT-203 for people with type 1 primary hyperoxaluria (PH1), a rare condition that causes high oxalate levels and can damage the kidneys. It aims to see if YOLT-203 can safely help manage the disease.
This trial tests a new intravenous medicine called YOLT-201 for people with a heart condition caused by buildup of a protein called transthyretin (ATTR-CM). The goal is to see if it can slow or improve the disease.
This trial tests a new treatment called ABO-101 for people with primary hyperoxaluria type 1, a rare disease that causes high oxalate levels in urine. The study aims to see if ABO-101 can lower oxalate and protect kidney function.
Hear when a new Primary Hyperoxaluria Type 1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.